	US 12,129,486 B2
	Methods for directed differentiation of pluripotent stem cells to immune cells
Maksym A. Vodyanyk, Madison, WI (US); Xin Zhang, Madison, WI (US); Andrew J. Brandl, Madison, WI (US); Deepika Rajesh, Madison, WI (US); Bradley Swanson, Madison, WI (US); Christie Munn, Madison, WI (US); Sarah A. Burton, Madison, WI (US); and Wen Bo Wang, Madison, WI (US)
Assigned to FUJIFILM Cellular Dynamics, Inc., Madison, WI (US)
Filed by FUJIFILM Cellular Dynamics, Inc., Madison, WI (US)
Filed on Oct. 5, 2020, as Appl. No. 17/063,204.
Application 17/063,204 is a continuation of application No. 15/769,386, granted, now 10,947,502, previously published as PCT/US2016/057899, filed on Oct. 20, 2016.
Claims priority of provisional application 62/404,470, filed on Oct. 5, 2016.
Claims priority of provisional application 62/244,101, filed on Oct. 20, 2015.
Prior Publication US 2021/0017494 A1, Jan. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); C12N 5/0781 (2010.01); C12N 5/0784 (2010.01); C12N 5/0789 (2010.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01)

CPC C12N 5/0636 (2013.01) [C12N 5/0635 (2013.01); C12N 5/0637 (2013.01); C12N 5/0638 (2013.01); C12N 5/0639 (2013.01); C12N 5/0646 (2013.01); C12N 5/0647 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); C12N 2500/38 (2013.01); C12N 2500/90 (2013.01); C12N 2501/115 (2013.01); C12N 2501/125 (2013.01); C12N 2501/145 (2013.01); C12N 2501/155 (2013.01); C12N 2501/165 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/25 (2013.01); C12N 2501/26 (2013.01); C12N 2501/60 (2013.01); C12N 2501/602 (2013.01); C12N 2501/603 (2013.01); C12N 2501/604 (2013.01); C12N 2501/605 (2013.01); C12N 2501/606 (2013.01); C12N 2501/608 (2013.01); C12N 2501/727 (2013.01); C12N 2501/998 (2013.01); C12N 2501/999 (2013.01); C12N 2506/025 (2013.01); C12N 2506/03 (2013.01); C12N 2506/09 (2013.01); C12N 2506/11 (2013.01); C12N 2506/45 (2013.01); C12N 2510/00 (2013.01); C12N 2533/50 (2013.01); C12N 2840/20 (2013.01)]

27 Claims

1. A method for providing an enriched population of lymphoid progenitors comprising:

(a) obtaining a starting cell population comprising lymphoid progenitors;

(b) enriching said starting cell population for lymphoid progenitors by performing magnetic-activated cell sorting (MACS) to isolate cells positive for at least two of the cell surface markers selected from the group consisting of CD31, CD34, CD144, CD43, CD45, CD7, CD235, Flk-1, and DLL4, thereby providing a population of cells with increased lymphoid potential as compared to an unsorted cell population or a population of cells negative for two more of the cell surface markers selected from the group consisting of CD31, CD34, CD144, CD43, CD45, CD7, CD235, Flk-1, and DLL4, wherein cells with increased lymphoid potential have an increased efficiency at producing T cells as measured by a ratio of input of HPCs to output of T cells.